These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Active immunization trial in Abeta42-injected P301L tau transgenic mice. Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870 [TBL] [Abstract][Full Text] [Related]
23. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695 [TBL] [Abstract][Full Text] [Related]
24. Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation. Osinde M; Clavaguera F; May-Nass R; Tolnay M; Dev KK Neuropathol Appl Neurobiol; 2008 Oct; 34(5):523-31. PubMed ID: 18282162 [TBL] [Abstract][Full Text] [Related]
25. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643 [TBL] [Abstract][Full Text] [Related]
26. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. van de Nes JA; Nafe R; Schlote W Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153 [TBL] [Abstract][Full Text] [Related]
27. [Tau story: from frontotemporal dementia to other tauopathies]. Buée L; Hamdane M; Delobel P; Sambo AV; Bégard S; Ghestem A; Sergeant N; Delacourte A J Soc Biol; 2002; 196(1):103-8. PubMed ID: 12134624 [TBL] [Abstract][Full Text] [Related]
29. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644 [TBL] [Abstract][Full Text] [Related]
30. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Padmanabhan J; Levy M; Dickson DW; Potter H Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932 [TBL] [Abstract][Full Text] [Related]
31. Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice. Katsuse O; Lin WL; Lewis J; Hutton ML; Dickson DW Neurosci Lett; 2006 Dec; 409(2):95-9. PubMed ID: 17010516 [TBL] [Abstract][Full Text] [Related]
32. [Animal models of tauopathies]. Higuchi M Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223 [TBL] [Abstract][Full Text] [Related]
33. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. Sydow A; Mandelkow EM Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454 [TBL] [Abstract][Full Text] [Related]
34. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Schwab C; Hosokawa M; McGeer PL Exp Neurol; 2004 Jul; 188(1):52-64. PubMed ID: 15191802 [TBL] [Abstract][Full Text] [Related]
35. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Maurage CA; Sergeant N; Ruchoux MM; Hauw JJ; Delacourte A Acta Neuropathol; 2003 Feb; 105(2):89-97. PubMed ID: 12536218 [TBL] [Abstract][Full Text] [Related]
36. [Drug development for tauopathy and Alzheimer's disease]. Takashima A Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Aug; 30(4):177-80. PubMed ID: 20857696 [TBL] [Abstract][Full Text] [Related]
37. Argyrophilic grains are not always argyrophilic--distinction from neurofibrillary tangles of diffuse neurofibrillary tangles with calcification revealed by comparison between Gallyas and Campbell-Switzer methods. Uchihara T; Tsuchiya K; Nakamura A; Akiyama H Acta Neuropathol; 2005 Aug; 110(2):158-64. PubMed ID: 15971055 [TBL] [Abstract][Full Text] [Related]
38. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. Köhler C; Bista P; Götz J; Schröder H Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372 [TBL] [Abstract][Full Text] [Related]
39. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. Tanemura K; Murayama M; Akagi T; Hashikawa T; Tominaga T; Ichikawa M; Yamaguchi H; Takashima A J Neurosci; 2002 Jan; 22(1):133-41. PubMed ID: 11756496 [TBL] [Abstract][Full Text] [Related]
40. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Maeda S; Sahara N; Saito Y; Murayama S; Ikai A; Takashima A Neurosci Res; 2006 Mar; 54(3):197-201. PubMed ID: 16406150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]